Cas:13343-66-3 benzyl 2-acetamido-2-deoxy-3,4,6-tri-o-acetyl-beta-d-glucopyranoside manufacturer & supplier

We serve Chemical Name:benzyl 2-acetamido-2-deoxy-3,4,6-tri-o-acetyl-beta-d-glucopyranoside CAS:13343-66-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

benzyl 2-acetamido-2-deoxy-3,4,6-tri-o-acetyl-beta-d-glucopyranoside

Chemical Name:benzyl 2-acetamido-2-deoxy-3,4,6-tri-o-acetyl-beta-d-glucopyranoside
CAS.NO:13343-66-3
Synonyms:7308p
Molecular Formula:C21H27NO9
Molecular Weight:437.44000
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:586.955ºC at 760 mmHg
Density:1.267g/cm3
Index of Refraction:1.532
PSA:126.46000
Exact Mass:437.16900
LogP:1.25020

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 7308p chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7308p physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7308p Use and application,7308p technical grade,usp/ep/jp grade.


Related News: China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%. benzyl 2-acetamido-2-deoxy-3,4,6-tri-o-acetyl-beta-d-glucopyranoside manufacturer It found that about 5% of both groups of women have a genetic mutation that increases the risk of breast cancer. benzyl 2-acetamido-2-deoxy-3,4,6-tri-o-acetyl-beta-d-glucopyranoside supplier The fine and functional chemicals sector provides new growth drivers. benzyl 2-acetamido-2-deoxy-3,4,6-tri-o-acetyl-beta-d-glucopyranoside vendor The fine and functional chemicals sector provides new growth drivers. benzyl 2-acetamido-2-deoxy-3,4,6-tri-o-acetyl-beta-d-glucopyranoside factory The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.